Highlights

  • HeartFlow shares increased after cardiology organizations addressed coronary plaque assessment importance.
  • Scientific statements focused on plaque quantification using cardiac CT imaging techniques.
  • FDA-cleared plaque analysis remains central to the company’s diagnostic platform.

HeartFlow Inc. (NASDAQ:HTFL) shares advanced about 9% on Thursday following disclosures related to recent scientific statements issued by two major cardiovascular organizations. The movement came after the American College of Cardiology (ACC) and the American Heart Association (AHA) published statements emphasizing the clinical relevance of quantifying coronary plaque in cardiovascular risk evaluation.

The statements were released through peer-reviewed medical journals and did not reference any single commercial provider. However, investor attention centered on how the broader guidance aligns with technologies currently used in cardiac imaging and diagnostics.

Emphasis on Coronary Plaque Evaluation
Coronary plaque refers to fatty deposits that accumulate in the arteries supplying blood to the heart. These deposits are associated with an increased risk of cardiovascular events and are commonly evaluated during diagnostic imaging procedures.

HeartFlow’s plaque analysis technology applies artificial intelligence to standard cardiac computed tomography (CT) scans. The system is designed to quantify plaque levels using imaging data already collected during routine clinical workflows. The plaque analysis product has received clearance from the U.S. Food and Drug Administration (FDA) and represents a key component of the company’s overall diagnostic offering.

Alignment With Published Clinical Guidance
In its disclosure, HeartFlow noted that the ACC and AHA statements highlighted the value of standardized reporting, consistency, and methodological rigor in plaque measurement. According to the company, its plaque analysis approach reflects these principles, including the use of algorithm-based thresholds and structured reporting methods.

The scientific statements focused on clinical methodology rather than commercial adoption. They addressed how plaque quantification can contribute to cardiovascular assessment when applied within established imaging standards.

Industry Context and Market Interpretation
In the healthcare diagnostics sector, guidance from physician-led organizations such as the ACC and AHA is often monitored closely by market participants. Such statements can influence how clinicians, imaging centers, and healthcare systems evaluate diagnostic tools, even when no regulatory or reimbursement changes are announced.

Market participants appeared to interpret the publication of these statements as relevant to companies operating in the cardiac imaging and artificial intelligence diagnostics space. The stock price reaction occurred without the release of updated financial projections, operational metrics, or revenue guidance.

Focus Going Forward
Following Thursday’s trading activity, attention around HeartFlow is likely to remain on how evolving clinical standards intersect with imaging practices and diagnostic workflows. The company’s performance may continue to reflect developments related to clinical research, regulatory positioning, and broader trends in AI-enabled healthcare diagnostics rather than short-term operational updates.

Share Price Snapshot
HTFL was trading 8.98% higher at USD 28.65 per share as of 18 December 2025.